The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC
February 7th 2013As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.
HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer
Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.
Potential Treatment Combinations for Melanoma Identified Through Novel Screening Approach
A new drug screening method revealed that cholesterol-reducing statin drugs used in combination with cyclin-dependent kinase inhibitors might serve as an effective treatment approach for certain types of melanoma.
Proto-oncogene Responsible for Ovarian Cancer Metastasis Identified
Activation of a signaling pathway involving the proto-oncogene Src is responsible for disease progression and metastasis in cancer and beta blocker drugs could be used to reduce mortality in these patients.
Dr. Grady Discusses Molecular Subtypes in Colorectal Cancer
January 25th 2013William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.
Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial
January 17th 2013Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.